- Home
- ACLS vs BEAM Comparison
ACLS vs BEAM Comparison
Compare ACLS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLS
- BEAM
- Stock Information
- Founded
- ACLS 1995
- BEAM 2017
- Country
- ACLS United States
- BEAM United States
- Employees
- ACLS N/A
- BEAM N/A
- Industry
- ACLS Industrial Machinery/Components
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACLS Technology
- BEAM Health Care
- Exchange
- ACLS Nasdaq
- BEAM Nasdaq
- Market Cap
- ACLS 2.3B
- BEAM 1.9B
- IPO Year
- ACLS 2000
- BEAM 2020
- Fundamental
- Price
- ACLS $71.12
- BEAM $24.45
- Analyst Decision
- ACLS Strong Buy
- BEAM Buy
- Analyst Count
- ACLS 6
- BEAM 10
- Target Price
- ACLS $156.00
- BEAM $47.67
- AVG Volume (30 Days)
- ACLS 574.6K
- BEAM 1.2M
- Earning Date
- ACLS 02-05-2025
- BEAM 02-25-2025
- Dividend Yield
- ACLS N/A
- BEAM N/A
- EPS Growth
- ACLS N/A
- BEAM N/A
- EPS
- ACLS 6.77
- BEAM N/A
- Revenue
- ACLS $1,075,736,000.00
- BEAM $349,643,000.00
- Revenue This Year
- ACLS N/A
- BEAM N/A
- Revenue Next Year
- ACLS N/A
- BEAM $14.08
- P/E Ratio
- ACLS $10.56
- BEAM N/A
- Revenue Growth
- ACLS N/A
- BEAM 328.73
- 52 Week Low
- ACLS $66.75
- BEAM $20.84
- 52 Week High
- ACLS $158.61
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- ACLS 45.69
- BEAM 43.38
- Support Level
- ACLS $66.75
- BEAM $22.50
- Resistance Level
- ACLS $74.22
- BEAM $24.60
- Average True Range (ATR)
- ACLS 2.42
- BEAM 1.51
- MACD
- ACLS 0.35
- BEAM -0.23
- Stochastic Oscillator
- ACLS 45.34
- BEAM 31.07
About ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provide aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services and customer training. Geographically, the group has a business presence in North America, Asia Pacific and Europe, of which key revenue is derived from the Asia Pacific.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.